Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 3.2%

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) traded down 3.2% during mid-day trading on Wednesday . The company traded as low as $29.04 and last traded at $29.16. 14,973 shares were traded during mid-day trading, a decline of 97% from the average session volume of 447,227 shares. The stock had previously closed at $30.13.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Finally, Citigroup raised their target price on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.33.

Arcturus Therapeutics Price Performance

The company has a market cap of $708.53 million, a PE ratio of -25.31 and a beta of 2.60. The company has a 50-day moving average of $35.42 and a 200 day moving average of $29.75.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($1.69) by $1.37. The company had revenue of $33.99 million during the quarter, compared to analyst estimates of $64.14 million. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. Equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -1.42 EPS for the current year.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the transaction, the chief operating officer now owns 473,448 shares in the company, valued at $16,580,148.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of ARCT. AJOVista LLC purchased a new stake in shares of Arcturus Therapeutics during the fourth quarter valued at $65,000. New York State Teachers Retirement System purchased a new position in Arcturus Therapeutics in the 3rd quarter worth approximately $53,000. Quest Partners LLC acquired a new position in Arcturus Therapeutics during the fourth quarter worth $67,000. Great West Life Assurance Co. Can raised its stake in Arcturus Therapeutics by 29.9% during the first quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 616 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new position in Arcturus Therapeutics during the fourth quarter worth about $89,000. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.